What AMIC offers patients with hip cartilage damage

Damaged hip cartilage does not heal itself. Unlike bone or muscle, the cartilage lining the hip joint has no blood supply to drive natural repair, so a full-thickness defect — whether caused by femoroacetabular impingement (FAI), a direct injury, or repetitive loading over years — will not recover without clinical intervention. For active adults typically aged between 18 and 50, the question becomes pressing: what can actually repair it, rather than simply manage the symptoms?

AMIC (Autologous Matrix-Induced Chondrogenesis) sits at the cartilage restoration stage of the hip treatment pathway — past the point where physiotherapy and pain relief are sufficient, but well before hip replacement becomes necessary. It is designed to address focal, full-thickness lesions at the acetabulum or femoral head: the kind of concentrated cartilage damage that threatens early joint deterioration if left untreated.

The defining feature for patients is that AMIC is delivered in a single operation. Older cell-based repair techniques require a biopsy appointment, a period of laboratory cell culture, and a separate implantation procedure. AMIC combines both stages into one, using the body's own biology — rather than externally processed cells — to drive repair at the defect site.

For someone facing a diagnosis of focal hip cartilage damage, AMIC represents the clearest surgical route toward preserving the hip joint and reducing the risk of early progression to arthritis.

How AMIC repairs cartilage in the hip joint

The repair process unfolds in two sequential steps, each with a distinct biological role.

Step one: microfracture. The surgeon uses a small pick or awl to create a series of tiny perforations in the subchondral bone — the layer immediately beneath the damaged cartilage. These perforations release bone marrow stem cells and growth factors into the defect, forming a blood-rich clot at the surface. The same marrow-stimulation technique is used in standard microfracture surgery; the hip joint's constant movement and shear forces, however, tend to displace or break down the clot before repair tissue can consolidate. This is the central mechanical problem that AMIC is designed to solve.

Step two: the scaffold. Once the clot has formed, the surgeon cuts and applies Chondro-Gide® — a resorbable bi-layer membrane made from natural porcine type I/III collagen fibres — directly over the defect. The porous side of the membrane faces the bone; fibrin glue secures the edges. The collagen membrane physically retains the marrow clot in place and creates a protected biological environment within the joint, shielding it from the shear forces that would otherwise disrupt a fragile new clot.

Within that protected space, the bone marrow stem cells are able to differentiate and gradually produce repair tissue that fills the defect. Over the following months, the collagen membrane is resorbed by the body and replaced by the patient's own tissue. No donor cartilage is used, no cells are removed and cultured in a laboratory, and no foreign material remains permanently in the joint — the process is fully autologous.

In the hip specifically, the scaffold is not an optional addition: it is what makes durable repair biologically viable. Without it, the marrow clot cannot survive the joint's mechanical environment long enough to generate lasting tissue.

Who is a suitable candidate for hip AMIC

Most candidates in published hip AMIC studies are men and women between 18 and 50 years old — the 2025 meta-analysis of 628 hips puts the weighted mean age at 35.8 years — who have sustained focal, full-thickness cartilage damage at the acetabulum or femoral head. The typical underlying cause is femoroacetabular impingement (FAI), though direct trauma and repetitive loading are also common triggers. Mean defect size across published series is approximately 3.3 cm², and AMIC is generally considered once a lesion reaches at least 2 cm²; below that threshold, microfracture alone or mosaicplasty may be the more appropriate option.

Equally important is the degree of background arthritis. AMIC is a cartilage repair procedure, not an arthritis treatment, and it requires a Tönnis grade of ≤2 to be viable. Tönnis grading classifies hip osteoarthritis on weight-bearing X-ray on a scale of 0 (normal) to 3 (severe joint destruction); once a hip reaches the upper end of grade 2 with meaningful joint space narrowing, cartilage repair — including AMIC — is generally no longer effective, and planning typically shifts toward joint replacement.

A practical self-check for readers: focal hip pain in an active person under 50, MRI-confirmed full-thickness cartilage loss of at least 2 cm², FAI or a specific injury as the most likely cause, and no advanced osteoarthritis on X-ray. Pre-operative MRI and weight-bearing imaging are what allow a surgeon to confirm lesion size and Tönnis grade — the two findings that determine whether AMIC is within reach or falls outside its indication.

What the clinical evidence shows for AMIC in the hip

Published data on hip AMIC have grown substantially in recent years, and the picture they paint is consistently positive — though not without acknowledged limitations.

The most comprehensive evidence comes from a 2025 systematic review and meta-analysis covering 628 hips across 12 studies. It reported a pooled success rate of 99.6% for AMIC and a mean improvement of 35.8 points on the modified Harris Hip Score (mHHS) — a validated measure of hip pain and everyday function that runs from 0 to 100. A gain of this magnitude represents a clinically meaningful shift from significant disability toward near-normal hip activity. A separate 2024 systematic review of 209 hips added arguably the most patient-relevant finding: in AMIC-treated groups, not a single patient went on to require a total hip replacement over follow-up periods of one to eight years. In microfracture-alone comparators from the same review, conversion rates to hip replacement ranged from 2% to 32.6%.

For durability, a single-centre case series of 201 patients followed for five years showed a mean mHHS gain of 39.1 points, with scores peaking at the three-year mark (85.5 on average) and holding at that level through five years.

MRI evaluation using the MOCART scoring system — which assesses the quality and extent of repair tissue — returned a mean score of 67.5 at five years in a mid-term study. Importantly, some patients with satisfactory clinical results showed structural changes including subchondral irregularity on imaging, a reminder that clinical and imaging outcomes do not always move in step.

Limitations to note plainly: the majority of studies are retrospective single-centre series, and large randomised controlled trials in the hip remain lacking. Evidence beyond seven to eight years in the hip specifically is limited. The NHS REPAIR pilot RCT (IRAS 326268, Northumbria Healthcare NHS Foundation Trust), comparing AMIC with microfracture alone in patients aged 18–40, is an early signal that mainstream NHS evaluation is under way.

AMIC versus other hip cartilage repair options

Choosing between cartilage repair options for the hip depends on three practical variables: lesion size, the biological quality of repair tissue required, and how many procedures a patient can reasonably undergo.

Microfracture alone

For lesions below 2 cm², microfracture remains in use, but its limitations are clinically significant. The fibrocartilage it generates tends to deteriorate within two to three years, and repeated subchondral perforations can degrade the bone plate underlying the defect — narrowing future repair options. AMIC addresses this directly: the collagen scaffold stabilises the marrow clot against the shear forces within the hip joint, supporting more durable tissue formation. The 2024 systematic review of 209 hips made the consequence visible in numbers: zero patients in the AMIC group required a total hip replacement over one to eight years of follow-up, against a conversion rate of 2%–32.6% in microfracture-alone comparators.

ACI and MACI

Autologous chondrocyte implantation (ACI) and its matrix-supported variant MACI carry a strong long-term evidence base but each demands two operations — biopsy, laboratory culture, then re-implantation weeks later — alongside greater resource intensity and cost. The 2025 meta-analysis of 628 hips found AMIC's pooled success rate of 99.6% marginally exceeded ACT's 98.3%, with a mean mHHS gain of 35.8 points against 31.1 for ACT, achieved without donor cartilage, cell culture, or a return to theatre.

OATS and mosaicplasty

Osteochondral autograft transfer (OATS) and mosaicplasty move full-thickness cartilage plugs from a low-load area of the same hip to the defect site — single-stage, and suited to lesions of roughly 1–2 cm², with mosaic configurations extending to approximately 4 cm². The central trade-off is donor-site morbidity: harvesting plugs creates a secondary wound that may cause its own pain or stiffness. Where lesion size overlaps — broadly the 2–4 cm² range — defect geometry can guide the decision: the acetabulum's curved, concave surface makes it technically difficult to seat cylindrical plugs flush, whereas the collagen membrane used in AMIC conforms to irregular contours without that constraint.

For mid-sized focal lesions at the acetabulum or femoral head, AMIC therefore avoids the durability ceiling of microfracture, the two-stage burden of ACI or MACI, and the donor-site problem inherent in autograft transfer — with the geometry of the acetabular surface adding a further practical argument on that specific surface.

The AMIC procedure and recovery pathway at Lincolnshire Hip

Surgery is most commonly performed arthroscopically — through small portal incisions, using a camera and fine instruments — though open surgical dislocation may be required for larger or anatomically complex defects. Where femoroacetabular impingement is the underlying cause, the bony impingement is corrected in the same operation: the femoral head or acetabular rim is reshaped before the cartilage repair is completed, addressing both the mechanical cause and the resulting damage under a single anaesthetic.

In the immediate postoperative period, patients use crutches and bear only partial weight through the hip for several weeks, protecting the scaffold and newly forming repair tissue before it has consolidated under load. Structured physiotherapy follows in phases — initial range-of-motion work, progressive strengthening, and eventually functional rehabilitation. Return to full activity, including physically demanding sport or work, typically takes a number of months rather than weeks; the precise timeline depends on lesion size, anatomical location, and how healing progresses individually.

Follow-up combines clinical hip outcome scores with MRI at defined intervals to monitor scaffold integration and repair tissue quality. Clinical progress and imaging findings each capture a different dimension of recovery and are reviewed alongside one another.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment, with clinics accessible from Sleaford and Grantham. For anyone at the decision stage, the most productive question to bring to a specialist assessment is whether defect size, grade, and underlying cause place single-stage cartilage repair within reach — before the window for joint preservation narrows further.

1. [1] Mid-term results of Autologous Matrix-Induced Chondrogenesis (AMIC) used for large chondral defects in femoroacetabular impingement hips. (2023). https://doi.org/10.1302/1358-992x.2023.12.029 https://doi.org/10.1302/1358-992x.2023.12.029
2. [2] Outcomes of autologous chondrocyte transplantation (ACT) and autologous matrix-induced chondrogenesis (AMIC) in the hip: a systematic review and meta-analysis. (2025). https://doi.org/10.1186/s13018-025-05862-5 https://doi.org/10.1186/s13018-025-05862-5
3. [3] Autologous Membrane Induced Chondrogenesis (AMIC) for the treatment of acetabular chondral defect. (2016). https://doi.org/10.11138/mltj/2016.6.3.367 https://doi.org/10.11138/mltj/2016.6.3.367
4. [4] Autologous Matrix-Induced Chondrogenesis for the Treatment of Hip Acetabular Chondral Lesions Demonstrates Improved Outcomes: A Systematic Review. (2024). https://doi.org/10.1016/j.arthro.2024.04.028 https://doi.org/10.1016/j.arthro.2024.04.028
5. [5] Arthroscopic treatment of chondral defects in the hip: AMIC, MACI, microfragmented adipose tissue transplantation (MATT) and other options. (2017). https://doi.org/10.1051/sicotj/2017029 https://doi.org/10.1051/sicotj/2017029